Ozempic vs Wegovy: Same Drug, Different Doses — What You Need to Know

How They Work

Ozempic and Wegovy are the same drug. Both contain semaglutide, a synthetic version of a hormone your body already makes called GLP-1 (glucagon-like peptide-1). Both are manufactured by Novo Nordisk in Denmark. Both are injected once per week using a prefilled pen. The molecule inside each pen is identical down to the amino acid sequence.

GLP-1 is released naturally by cells in your gut after you eat. It performs three jobs simultaneously. It tells your pancreas to release insulin in proportion to your meal. It signals satiety centers in your brain, specifically the hypothalamus, that you have eaten enough. And it slows gastric emptying, meaning food stays in your stomach longer so you feel full for a longer period after eating.

Natural GLP-1 breaks down in the body within minutes. Semaglutide was engineered to resist that breakdown. Novo Nordisk modified the GLP-1 molecule by attaching a fatty acid chain that binds to albumin, a protein in your blood. This albumin binding acts as a shield, giving semaglutide a half-life of approximately seven days. One injection per week maintains steady-state receptor activation that native GLP-1 could never achieve.

That prolonged activity produces two main clinical effects. First, blood sugar control improves because insulin release is tightly coupled to meals and glucagon secretion is suppressed. Second, appetite drops significantly and consistently. People on semaglutide report feeling full sooner, thinking about food less often, and losing interest in snacking between meals. Brain imaging studies have shown that semaglutide reduces activity in brain regions associated with food reward and craving. These are not separate drugs for separate problems. They are the same molecule doing the same thing in two different patient populations.

The pharmacological result is a drug that reduces HbA1c (a marker of long-term blood sugar control) by roughly 1.5 to 2 percentage points in people with Type 2 diabetes, and produces average body weight reductions of 10-15% in people with obesity. Both effects stem from the same GLP-1 receptor activation. There is no "diabetes version" and "weight loss version" of semaglutide. There is one molecule that does both.

The only meaningful difference between Ozempic and Wegovy is what is printed on the label. Ozempic is approved for Type 2 diabetes. Wegovy is approved for chronic weight management. The FDA treats them as distinct products with separate approval pathways, different National Drug Codes, different dose ranges, and different insurance formulary positions. But pharmacologically, they are interchangeable.

What Actually Differs: Doses and Indications

The FDA approved Ozempic in December 2017 for adults with Type 2 diabetes as an adjunct to diet and exercise. Its approved maintenance doses are 0.5 mg, 1.0 mg, and 2.0 mg per week. The 2.0 mg dose was added later, in March 2022. The standard titration starts at 0.25 mg for four weeks (a sub-therapeutic dose meant solely to reduce gastrointestinal side effects), then moves to 0.5 mg. From there, a prescriber can increase to 1.0 mg after at least four weeks, and again to 2.0 mg if additional glycemic control is needed. Most Ozempic patients stabilize at either 0.5 mg or 1.0 mg for diabetes management.

Wegovy received FDA approval for chronic weight management in June 2021. It is indicated for adults with a BMI of 30 or higher (obesity), or a BMI of 27 or higher (overweight) with at least one weight-related comorbidity such as hypertension, Type 2 diabetes, dyslipidemia, or obstructive sleep apnea. In late 2022, the FDA also approved Wegovy for adolescents aged 12 and older meeting the same BMI criteria. Wegovy uses a slower, five-step titration schedule designed to minimize nausea: 0.25 mg for four weeks, 0.5 mg for four weeks, 1.0 mg for four weeks, 1.7 mg for four weeks, then 2.4 mg as the ongoing maintenance dose. The full titration takes 16 weeks before a patient reaches the target dose.

That extra 0.4 mg between Ozempic's ceiling (2.0 mg) and Wegovy's maintenance dose (2.4 mg) matters more than it appears. Clinical trial data consistently shows that weight loss with semaglutide is dose-dependent. Higher doses produce greater appetite suppression and greater total body weight reduction. The jump from 2.0 mg to 2.4 mg is a 20% increase in dose. The STEP 1 trial, which tested the 2.4 mg dose in adults with obesity, showed an average weight loss of 14.9% of body weight at 68 weeks. No Ozempic trial at the 2.0 mg dose has produced that result. The 1.7 mg step that exists only in the Wegovy titration is also significant. It gives the body an intermediate adaptation period that Ozempic's titration skips entirely.

In practice, many physicians prescribe Ozempic off-label for weight loss. This is legal and common. Doctors can prescribe any FDA-approved medication for any condition they judge clinically appropriate. Off-label Ozempic use for weight management became widespread starting in 2022, driven by two converging forces: chronic Wegovy supply shortages that left patients unable to fill prescriptions, and the reality that insurance companies were far more likely to cover an Ozempic prescription classified under diabetes benefits than a Wegovy prescription classified under obesity benefits. The tradeoff is clear. Off-label Ozempic caps at 2.0 mg, meaning patients miss both the 1.7 mg adaptation step and the full 2.4 mg maintenance dose.

In January 2024, the FDA expanded Wegovy's indication to include reduction of cardiovascular risk. Specifically, Wegovy is now approved to reduce the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease who are overweight or obese. This made Wegovy the first anti-obesity medication in history to carry an approved cardiovascular benefit claim. Ozempic does not carry this indication, despite containing the same active ingredient. The distinction matters for insurance appeals and coverage decisions.

Insurance, Cost, and Access

This is where the real decision happens for most people. The drug is identical. The dose difference is meaningful but modest. What actually determines whether someone ends up on Ozempic or Wegovy is almost always insurance coverage and out-of-pocket cost.

Ozempic generally has broader and more predictable insurance coverage because it is classified as a diabetes medication. Most commercial insurance plans, Medicare Part D, and Medicaid programs cover diabetes drugs as a standard formulary category. If a patient has a Type 2 diabetes diagnosis, getting Ozempic approved is usually straightforward. Some plans require prior authorization. Some impose step therapy, meaning the patient must try metformin or another first-line drug before the insurer will approve semaglutide. But the pathway is well-established and widely understood by prescribers and pharmacies.

Wegovy coverage is a different landscape. For decades, most insurance plans explicitly excluded anti-obesity medications from their formularies. Obesity was not recognized as a disease requiring pharmaceutical intervention by many payers. That picture has been shifting since 2023. Several major commercial insurers, including some Blue Cross Blue Shield plans, United Healthcare, and Aetna, have expanded coverage for FDA-approved anti-obesity medications. The Treat and Reduce Obesity Act, which would require Medicare to cover these drugs, has been introduced in Congress multiple times but had not been enacted as of early 2026. Coverage remains inconsistent. Some plans cover Wegovy only after documented failure of a structured diet and exercise program lasting six months or more. Some require a BMI above 35 rather than the FDA-approved threshold of 30. Some require the prescriber to be an endocrinologist or obesity medicine specialist. And some plans still exclude anti-obesity drugs entirely. Patients frequently discover their specific coverage status only after their doctor submits the prescription and the pharmacy processes the claim.

Without insurance, both drugs carry significant costs. Ozempic has a wholesale acquisition cost (WAC) of approximately $935 per month. Wegovy lists at roughly $1,350 per month. Novo Nordisk offers patient savings programs for commercially insured individuals that can reduce out-of-pocket costs to as little as $25 per month for eligible patients. However, these manufacturer coupons typically do not apply to patients on government insurance (Medicare, Medicaid, Tricare) or those without any insurance. For those populations, the full retail price applies, and it is prohibitive for most households.

Compounded semaglutide has emerged as a significant third option. Under Section 503A and 503B of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies can produce copies of FDA-approved drugs during periods of recognized drug shortage. Compounded semaglutide typically costs between $150 and $500 per month depending on the pharmacy, formulation, and dose. The FDA maintains a Drug Shortage Database that lists the current status of semaglutide products. That status has fluctuated, and the regulatory landscape around compounded GLP-1 agonists continues to evolve. Patients considering this route should verify that their pharmacy is a state-licensed 503A pharmacy (requires a valid patient-specific prescription) or an FDA-registered 503B outsourcing facility (subject to cGMP standards and FDA inspections). Quality and potency can vary between compounders, which is a tradeoff patients need to weigh against the significant cost savings.

One additional access consideration: Novo Nordisk has periodically faced supply constraints on both Ozempic and Wegovy due to surging demand. During peak shortage periods in 2023 and 2024, certain dose strengths were unavailable for weeks at a time. Patients mid-titration sometimes could not fill their next dose step, forcing them to hold at a lower dose or temporarily pause treatment. Supply has stabilized somewhat, but stock levels at individual pharmacies can still fluctuate. Patients starting either medication should ask their prescriber about contingency plans if their dose becomes temporarily unavailable.

Clinical Trial Evidence

The strongest weight loss evidence for semaglutide at the 2.4 mg dose comes from the STEP (Semaglutide Treatment Effect in People with Obesity) trial program. This was a series of Phase 3 clinical trials specifically designed to support the Wegovy approval.

STEP 1 enrolled 1,961 adults with obesity (BMI of 30 or above) or overweight with at least one comorbidity. Participants did not have diabetes. Over 68 weeks, those randomized to semaglutide 2.4 mg lost an average of 14.9% of their body weight, compared to 2.4% in the placebo group. Roughly one-third of participants lost more than 20% of body weight. The most common side effects were gastrointestinal: nausea (44% vs 18% placebo), diarrhea (30% vs 16%), and vomiting (24% vs 6%). Most GI events occurred during dose escalation and were rated as mild to moderate. The results were published in the New England Journal of Medicine in February 2021 (PMID: 33567185).

STEP 2 focused on adults who had both Type 2 diabetes and obesity. Weight loss was more modest at 9.6% with the 2.4 mg dose over 68 weeks. This is consistent with the well-documented pattern that people with Type 2 diabetes tend to lose less weight on GLP-1 medications than people without diabetes, likely due to the effects of insulin resistance and diabetes medications on body weight regulation.

STEP 3 combined semaglutide 2.4 mg with intensive behavioral therapy, including an initial low-calorie diet phase and 30 counseling sessions. This group achieved 16% average weight loss at 68 weeks, demonstrating an additive benefit when the drug is paired with structured lifestyle intervention. STEP 4 used a withdrawal design: all participants received semaglutide for 20 weeks, then were randomized to continue or switch to placebo. Those who continued lost a total of 17.4% body weight by week 68. Those who switched to placebo regained roughly two-thirds of their lost weight over the following 48 weeks. This trial confirmed what many suspected: semaglutide must be taken continuously to maintain its weight loss effects.

STEP 5 extended the treatment duration to 104 weeks (two years) and showed sustained weight loss of 15.2% at the end of the study, indicating that the weight loss achieved in the first year is largely maintained through the second year as long as the patient stays on the medication.

Ozempic's clinical foundation rests on the SUSTAIN (Semaglutide Unabated Sustainability in Treatment of Type 2 Diabetes) trial program. SUSTAIN 1 through SUSTAIN 10 evaluated semaglutide at doses of 0.5 mg and 1.0 mg (and later 2.0 mg in SUSTAIN FORTE) primarily for blood sugar reduction measured by HbA1c, with weight loss tracked as a secondary endpoint. In SUSTAIN 1, patients on 1.0 mg semaglutide lost an average of 4.5 kg (approximately 10 pounds) over 30 weeks. SUSTAIN 2 showed weight loss of 6.1 kg on the 1.0 mg dose at 56 weeks. SUSTAIN FORTE, which tested the 2.0 mg dose head-to-head against 1.0 mg in patients with inadequately controlled Type 2 diabetes, showed additional HbA1c reduction and a modest increase in weight loss with the higher dose. The weight loss numbers from SUSTAIN are uniformly lower than STEP because the doses were lower and the patient population had diabetes.

The SELECT trial is the landmark cardiovascular outcomes study and arguably the most important semaglutide trial published to date. Published in the New England Journal of Medicine in November 2023 (PMID: 37952131), SELECT enrolled 17,604 adults aged 45 and older who had established cardiovascular disease (prior heart attack, stroke, or peripheral artery disease), a BMI of 27 or greater, and no diabetes. Participants were randomized to semaglutide 2.4 mg weekly or placebo and followed for a median of 39.8 months. The primary endpoint was a composite of cardiovascular death, nonfatal heart attack, and nonfatal stroke. Semaglutide reduced this composite endpoint by 20% (hazard ratio 0.80, 95% CI 0.72-0.90). The weight loss in SELECT averaged 9.4% with semaglutide versus 0.9% with placebo. SELECT was the trial that secured Wegovy's expanded cardiovascular indication. It also provides the most compelling clinical argument for the 2.4 mg dose: the cardiovascular benefit was demonstrated specifically at the Wegovy dose, not the Ozempic doses.

The Bottom Line

Ozempic and Wegovy are the same molecule made by the same company injected the same way on the same schedule. The pharmacology is identical. If you extracted the semaglutide from both pens and analyzed it in a lab, there would be nothing to distinguish them.

The practical differences are regulatory, financial, and dosing-related. Wegovy goes to a higher maintenance dose (2.4 mg vs 2.0 mg), carries the FDA-approved indication for chronic weight management, includes a more gradual five-step titration, and now holds an approved cardiovascular risk reduction claim based on the SELECT trial. Ozempic often wins on access because diabetes medications have a well-established insurance coverage pathway that anti-obesity drugs are still catching up to.

For most patients, the deciding factor is not which product is pharmacologically superior. It is which one their insurance plan will authorize and which one their pharmacy can keep in stock. If you have Type 2 diabetes, Ozempic is the straightforward on-label choice and typically the path of least resistance through insurance. If weight loss is the primary goal, Wegovy at 2.4 mg is the dose studied in the STEP trials and the SELECT cardiovascular outcomes trial, and it carries the on-label indication to match.

People who are currently on off-label Ozempic for weight loss and doing well do not necessarily need to switch. But they should understand that their dose ceiling is lower than what the clinical trials tested for weight management, and that the cardiovascular benefit data was generated at 2.4 mg. If the opportunity to switch to Wegovy arises through insurance changes or improved availability, it is worth discussing with your prescriber.

The right starting point is a conversation with your doctor, who can evaluate your clinical profile, check your insurance formulary, and navigate the specific coverage rules that apply to your plan.